LAHAN - CDPH Health Update: Use of Outpatient COVID-19 Therapeutics in California April 1, 2022 California, California Department of Public Health, COVID-19, EUA, FDA, LAC DPH, Los Angeles, Los Angeles County, Public Health, SARS-CoV-2, Therapeutics 936 The California Department of Public Health (CDPH) issued an update on the status of COVID-19 therapeutics in California, including the following key points: There is no longer a limited supply of COVID-19 therapeutics in most locations. At this time, all outpatients with mild to moderate COVID-19 who are at risk for disease progression should be offered treatment, if eligible, based on the product EUA. Sotrovimab is no longer authorized by the FDA for use in California due to increases of the Omicron sub-variant BA.2. A new HHS Test to Treat Locator went live on 3/30/2022. This locator identifies facilities that can both test for SARS-CoV-2 and dispense COVID-19 therapeutics. In LA County, facilities that are interested in becoming a Test to Treat provider or that would like to receive Paxlovid, molnupiravir or Evusheld can contact LAC DPH at DPH-Therapeutics@ph.lacounty.gov. Visit the LAC DPH Monoclonal & Antiviral Therapy for Non-Hospitalized Patients website for additional information regarding therapeutics in LA County. Read the full CDPH update "Use of Outpatient COVID-19 Therapeutics in California"